Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review.

Rodrigo GJ, Neffen H, Castro-Rodriguez JA.

Chest. 2011 Jan;139(1):28-35. doi: 10.1378/chest.10-1194. Epub 2010 Aug 5. Review.

PMID:
20688929
2.

Omalizumab for asthma in adults and children.

Normansell R, Walker S, Milan SJ, Walters EH, Nair P.

Cochrane Database Syst Rev. 2014 Jan 13;(1):CD003559. doi: 10.1002/14651858.CD003559.pub4. Review.

PMID:
24414989
3.

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.

Pediatrics. 2001 Aug;108(2):E36.

PMID:
11483846
4.

Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents.

Rodrigo GJ, Neffen H.

Pediatr Allergy Immunol. 2015 Sep;26(6):551-6. doi: 10.1111/pai.12405. Epub 2015 Jul 1. Review.

PMID:
25963882
5.

Anti-IgE for chronic asthma in adults and children.

Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH.

Cochrane Database Syst Rev. 2004;(3):CD003559. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD003559.

PMID:
15266491
6.

Anti-IgE for chronic asthma in adults and children.

Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003559. Review. Update in: Cochrane Database Syst Rev. 2014;1:CD003559.

PMID:
16625585
7.

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.

Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF.

J Allergy Clin Immunol. 2009 Dec;124(6):1210-6. doi: 10.1016/j.jaci.2009.09.021.

PMID:
19910033
8.

Omalizumab is effective in the long-term control of severe allergic asthma.

Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N.

Ann Allergy Asthma Immunol. 2003 Aug;91(2):154-9.

PMID:
12952109
9.

Anti-IgE for chronic asthma.

Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH.

Cochrane Database Syst Rev. 2003;(3):CD003559. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD003559.

PMID:
12917972
10.

Spotlight on omalizumab in allergic asthma.

Bang LM, Plosker GL.

BioDrugs. 2004;18(6):415-8. Review.

PMID:
15571425
11.

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W.

Ann Intern Med. 2011 May 3;154(9):573-82. doi: 10.7326/0003-4819-154-9-201105030-00002.

12.

Omalizumab: a review of its use in the management of allergic asthma.

Bang LM, Plosker GL.

Treat Respir Med. 2004;3(3):183-99. Review.

PMID:
15219177
13.

Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.

Massanari M, Kianifard F, Zeldin RK, Geba GP.

Allergy Asthma Proc. 2009 Sep-Oct;30(5):534-9. doi: 10.2500/aap.2009.30.3245. Epub 2009 May 22.

PMID:
19467177
14.

Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.

Kulus M, Hébert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M.

Curr Med Res Opin. 2010 Jun;26(6):1285-93. doi: 10.1185/03007991003771338.

PMID:
20377320
15.

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.

Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD; Omalizumab 011 International Study Group..

Clin Exp Allergy. 2004 Apr;34(4):632-8.

PMID:
15080818
16.

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.

Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G.

Eur Respir J. 2001 Aug;18(2):254-61. Erratum in: Eur Respir J 2001 Oct;18(4):739-40.

17.

Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.

Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J.

Curr Med Res Opin. 2001;17(4):233-40.

PMID:
11922396
18.

Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.

Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H.

Pediatrics. 2004 Apr;113(4):e308-12.

PMID:
15060258
19.

Omalizumab improves asthma-related quality of life in children with allergic asthma.

Lemanske RF Jr, Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N.

Pediatrics. 2002 Nov;110(5):e55.

PMID:
12415061
20.

Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma.

Grossman HL, Schlender A, Alperin P, Stanley EL, Zhang J.

Curr Med Res Opin. 2010 Dec;26(12):2779-93. doi: 10.1185/03007995.2010.526101. Epub 2010 Nov 4.

PMID:
21050061

Supplemental Content

Support Center